KN-026
Highest phase reached
Phase 3
Drug type
Unknown
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Unknown
- Drug name
- KN-026
- anbenitamab
- Anbenitamab
- anti her2 bsab kn026
- Anti-her2 bsab kn026
- kn 026
- Kn 026
- Kn-026
- KN-026
- kn026
- Kn026
- KN026
- ChEMBL ID
- CHEMBL4594568
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- Action type
- Inhibitor
- Target
- Receptor tyrosine-protein kinase erbB-2
- Protein identifier
- P04626
Open Targets mechanisms
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- Action type
- Inhibitor
- Target
- Receptor tyrosine-protein kinase erbB-2
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Adenocarcinoma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0003219
- Subject identifier
- D000230
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 3
- NCT03925974
- NCT04165993
- NCT04881929
- NCT05838066
- NCT04521179
- NCT05427383
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (16)
- A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
- A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
- A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
- JSKN003 Combined Treatment of HER2-positive Gastric Cancer
- KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor
- KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
- KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
- KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer
- KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
- Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
- Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
- Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
- Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
- Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
In development for (4)
- Breast cancer Phase 3
- Gastric cancer Phase 2
- Gastroesophageal junction adenocarcinoma Phase 2
- Neoplasm Phase 2
Targets (1)
- ERBB2 Receptor protein-tyrosine kinase erbB-2 inhibitor